AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.
EGFR Inhibitors Related Products:
PD153035; Nazartinib; Erlotinib; CL-387785; AZ-5104; ARRY-380 analog; MTX-211; Osimertinib; Osimertinib mesylate; Olmutinib; Afatinib Dimaleate; Rociletinib; EGFR-IN-7